MedTrace Logo

Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

NCT05473806 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-07-26

No results posted yet for this study

Summary

An exploratory comparison of changes in liver fibrosis through glycemic control within and between groups after administration of Pioglitazone and Evogliptin in chronic hepatitis B patients with type 2 diabetes and liver fibrosis

Conditions

  • Hepatitis B, Chronic
  • Fibrosis, Liver
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Pioglitazone 15 Mg Oral Tablet

24weeks dose

DRUG

Evogliptin 5mg

24weeks dose

Sponsors & Collaborators

  • Seung Up Kim

    lead OTHER

Principal Investigators

  • Seung Up Kim · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-18
Primary Completion
2023-01-19
Completion
2023-02-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05473806 on ClinicalTrials.gov